ClinicalTrials.gg
CompletedNCT01254188ENESTxtndUpdated Mar 3, 2016Results posted

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

A Phase 3 interventional study of Nilotinib in Chronic Myeloid Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 100 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
421
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
5th of 66
421 · median 55
Started
2011
with 3 others
Phase 3
15 of 66
none open now
Registered
24th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 5th largest by enrollment, is one of 4 that started in 2011, is one of 15 in phase 3, and was the 24th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

This study will further investigate the safety and efficacy of nilotinib in newly diagnosed chronic myeloid leukemia patients in the chronic phase

03

Conditions studied

  • Chronic Myeloid Leukemia

Keywords

  • Chronic myeloid leukemia,
  • CML,
  • nilotinib,
  • myelogenous,
  • Philadelphia chromosome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Patients with chronic myeloid leukemia in the chronic phase diagnosed within 6 months of study entry

Exclusion criteria

Exclusion Criteria:

  • Treatment with tyrosine kinase inhibitor or other antileukemic agents or treatments (including ) for longer than 2 weeks, with exception of hydroxyurea and/or anagrelide
  • Uncontrolled congestive heart failure or hypertension
  • Myocardial infarction or unstable angina pectoris within past 12 months
  • Known T315I mutations
  • >450 msec
  • Significant arrhythmias

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
421 participants (actual)

Study arms

  • Experimental
    Nilotinib

    300 mg BID

    Drug: Nilotinib

Interventions

  • This was an open-label, single-arm, prospective, multi-center, Phase IIIb clinical study with nilotinib 300 mg bid treatment in newly diagnosed CML-CP patients not previously treated with imatinib therapy and diagnosed within 6 months of study entry. For patients insufficiently responding to nilotinib 300 mg bid, the dose may have been increased to 400 mg bid. Among patients with adverse events who had dose reduction, this study also allowed a possible re-escalation to 300 mg bid.

    Also known as: AMN107

06

What researchers measure

Primary outcomes

  1. The Percentage of Patients Achieving MMR by 12 Months

    MMR is defined as BCR-ABL ratio (%) on IS \<= 0.1% (corresponds to \>=3 log reduction of BCR-ABL transcripts from standardized baseline value). Clopper-Pearson method

    Time frame: 12 months

Secondary outcomes

  1. Time to Molecular Response at 24 Months

    Estimated median time to first MMR by Kaplan-Meier method

    Time frame: 24 months

  2. Duration of Major Molecular Response

    Kaplan-Meier estimates of duration of first MMR among patients who achieved MMR (FAS) Duration of first MMR (months) = (Minimum date of (loss of first MMR , CML-related death, progression to AP/BC during study treatment, censoring) - date of first MMR + 1) / 30.4375

    Time frame: 3, 6, 9, 12, 15, 18, 21, 24 Months after MMR was detected

  3. Complete Cytogenetic Response

    Complete cytogenetic response (CCyR) is defined as a value of 0% Ph+ metaphases in bone marrow.

    Time frame: 6 months

  4. Percentage of Participants Estimated to Maintain Their First CCyR for 6, 12, 18, and 24 Months After the First CCyR Was Achieved as Determined by Kaplan Meier Estimatation.

    \* CCyR = 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics. Duration of first CCyR (months) = (date of CCyR loss or censoring - date of first CCyR +1) / 30.4375

    Time frame: 6,12,18 and 24 months

  5. Overall Survival

    OS was defined as the time between date of study entry and date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment.

    Time frame: 3, 6, 9, 12, 15, 18, 21, 24 Months

  6. Kaplan-Meier Estimates of Progression-free Survival

    PFS was defined as the time from the date of study entry to the date of event defined as the first documented disease progression to AP/BC or the date of death from any cause occurring on treatment.

    Time frame: 3,6,9,12,15,18,21,and 24 months

  7. Kaplan-Meier Estimates of Failure-free Survival

    Time to event (months) = (date of event or censoring - date of study entry + 1) / 30.4375. Date of event is the earliest date of the following events during treatment : discontinuation of nilotinib for nilotinib-related adverse events, death due to any cause, progression to AP or BC, loss of PCyR, loss of CCyR, loss of CHR. Time is censored at the date of last assessment in the trial for patients without event.

    Time frame: 3,6,9,12,15,18,21,and 24 months

07

Results

Posted Mar 3, 2016

Participant flow

Participant flow — Overall Study
MilestoneNilotinib
Started421
Completed328
Not completed93
Withdrew: Disease progression6
Withdrew: Protocol violation6
Withdrew: Pregnancy2
Withdrew: Death4
Withdrew: Lost to follow-up5
Withdrew: Withdrawal by subject7
Withdrew: Adverse event43
Withdrew: Per investigator discretion20

Outcome measures

PrimaryThe Percentage of Patients Achieving MMR by 12 Months

MMR is defined as BCR-ABL ratio (%) on IS \<= 0.1% (corresponds to \>=3 log reduction of BCR-ABL transcripts from standardized baseline value). Clopper-Pearson method

Time frame:
12 months
Reported as:
Number · percentage of participants
The Percentage of Patients Achieving MMR by 12 Months
percentage of participantsNilotinib
The Percentage of Patients Achieving MMR by 12 Months70.8 (66.1 to 75.2)
SecondaryTime to Molecular Response at 24 Months

Estimated median time to first MMR by Kaplan-Meier method

Time frame:
24 months
Reported as:
Median · Months
Time to Molecular Response at 24 Months
MonthsNilotinib
Time to Molecular Response at 24 Months6.0 (5.9 to 6.1)
SecondaryDuration of Major Molecular Response

Kaplan-Meier estimates of duration of first MMR among patients who achieved MMR (FAS) Duration of first MMR (months) = (Minimum date of (loss of first MMR , CML-related death, progression to AP/BC during study treatment, censoring) - date of first MMR + 1) / 30.4375

Time frame:
3, 6, 9, 12, 15, 18, 21, 24 Months after MMR was detected
Reported as:
Number · percentage of participants
Duration of Major Molecular Response
percentage of participantsNilotinib
K-M Estimate for 3 Month Duration100 (100 to 100)
K-M Estimate for 6 Month Duration97.1 (65.2 to 99.0)
K-M Estimate for 9 Month Duration92.8 (89.9 to 95.7)
K-M Estimate for 12 Month Duration92.1 (89.1 to 95.1)
K-M Estimate for 15 Month Duration91.7 (88.5 to 94.8)
18 months90.8 (87.4 to 94.1)
K-M Estimate for 21 Month Duration89.7 (85.7 to 93.6)
K-M Estimate for 24 Month Duration85.2 (75.8 to 94.5)
SecondaryComplete Cytogenetic Response

Complete cytogenetic response (CCyR) is defined as a value of 0% Ph+ metaphases in bone marrow.

Time frame:
6 months
Reported as:
Number · percentage of participants
Complete Cytogenetic Response
percentage of participantsNilotinib
Complete Cytogenetic Response58.7 (53.8 to 63.4)
SecondaryPercentage of Participants Estimated to Maintain Their First CCyR for 6, 12, 18, and 24 Months After the First CCyR Was Achieved as Determined by Kaplan Meier Estimatation.

\* CCyR = 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics. Duration of first CCyR (months) = (date of CCyR loss or censoring - date of first CCyR +1) / 30.4375

Time frame:
6,12,18 and 24 months
Reported as:
Number · percentage of participants
Percentage of Participants Estimated to Maintain Their First CCyR for 6, 12, 18, and 24 Months After the First CCyR Was Achieved as Determined by Kaplan Meier Estimatation.
percentage of participantsNilotinib
6 mos after the first CCyR was achieved100 (100 to 100)
12 mos after the first CCyR was achieved99.6 (98.8 to 100)
18 mos after the first CCyR was achieved98.7 (97.1 to 100)
24 mos after the first CCyR was achieved98.7 (97.1 to 100)
SecondaryOverall Survival

OS was defined as the time between date of study entry and date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment.

Time frame:
3, 6, 9, 12, 15, 18, 21, 24 Months
Reported as:
Number · percentage probability
Overall Survival
percentage probabilityNilotinib
3 months K-M Estimate99.8 (99.3 to 100)
6 months K-M Estimate99.5 (98.9 to 100)
9 months K-M Estimate99.5 (98.9 to 100)
12 months K-M Estimate99.0 (98.0 to 100)
15 months K-M Estimate98.2 (96.9 to 99.5)
18 months K-M Estimate97.6 (96.1 to 99.2)
21 months K-M Estimate97.6 (96.1 to 99.2)
24 months K-M Estimate97.6 (96.1 to 99.2)
SecondaryKaplan-Meier Estimates of Progression-free Survival

PFS was defined as the time from the date of study entry to the date of event defined as the first documented disease progression to AP/BC or the date of death from any cause occurring on treatment.

Time frame:
3,6,9,12,15,18,21,and 24 months
Reported as:
Number · percentage probability
Kaplan-Meier Estimates of Progression-free Survival
percentage probabilityNilotinib
3 mos99.7 (99.3 to 100)
6 mos99.5 (98.8 to 100)
9 mos98.9 (97.8 to 100)
12 mos98.6 (97.4 to 99.8)
15 mos98.0 (96.5 to 99.5)
18 mos97.6 (96.0 to 99.3)
21 mos97.6 (96.0 to 99.3)
24 mos97.0 (95.1 to 98.8)
SecondaryKaplan-Meier Estimates of Failure-free Survival

Time to event (months) = (date of event or censoring - date of study entry + 1) / 30.4375. Date of event is the earliest date of the following events during treatment : discontinuation of nilotinib for nilotinib-related adverse events, death due to any cause, progression to AP or BC, loss of PCyR, loss of CCyR, loss of CHR. Time is censored at the date of last assessment in the trial for patients without event.

Time frame:
3,6,9,12,15,18,21,and 24 months
Reported as:
Number · percentage probability
Kaplan-Meier Estimates of Failure-free Survival
percentage probabilityNilotinib
3 mos97.4 (95.8 to 98.9)
6 mos95.9 (93.9 to 97.8)
9 mos94.6 (92.4 to 96.8)
12 mos93.6 (91.2 to 96.0)
15 mos92.0 (89.4 to 94.7)
18 mos91.0 (88.2 to 93.8)
21 mos89.7 (86.6 to 92.7)
24 mos88.8 (85.7 to 92.0)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib—97/421 (23%)357/421 (84.8%)
Most frequent serious events
Showing 10 of 96
Most frequent serious events
EventNilotinib
THROMBOCYTOPENIABlood and lymphatic system disorders12/421
PANCREATITISGastrointestinal disorders7/421
ANAEMIABlood and lymphatic system disorders4/421
FEBRILE NEUTROPENIABlood and lymphatic system disorders4/421
ATRIAL FIBRILLATIONCardiac disorders4/421
PNEUMONIAInfections and infestations4/421
NEUTROPENIABlood and lymphatic system disorders3/421
ANGINA UNSTABLECardiac disorders3/421
PYREXIAGeneral disorders3/421
BLAST CELL CRISISNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/421
Most frequent other events
Showing 10 of 32
Most frequent other events
EventNilotinib
THROMBOCYTOPENIABlood and lymphatic system disorders78/421
HEADACHENervous system disorders77/421
RASHSkin and subcutaneous tissue disorders76/421
LIPASE INCREASEDInvestigations66/421
NAUSEAGastrointestinal disorders60/421
CONSTIPATIONGastrointestinal disorders51/421
ALANINE AMINOTRANSFERASE INCREASEDInvestigations51/421
ALOPECIASkin and subcutaneous tissue disorders50/421
PRURITUSSkin and subcutaneous tissue disorders50/421
FATIGUEGeneral disorders48/421

Baseline characteristics

Newly diagnosed CML-CP patients not previously treated with imatinib and diagnosed within 6 months of study entry, except for hydroxyurea, and/or anagrelide . In emergent cases where the patient requires disease management Gleevec/Glivec at any dose may be prescribed to the patient for no longer than 2 weeks in duration

Age, Categorical
Age, Categorical(Participants)Nilotinib
<=18 years0
Between 18 and 65 years368
>=65 years53
Age, Continuous
Age, Continuous(years)Nilotinib
Mean47.13 ± 14.892
Sex: Female, Male
Sex: Female, Male(Participants)Nilotinib
Female195
Male226
08

Study locations

100 sites
  • Novartis Investigative Site
    Alger, Bouzareah 16000, Algeria
  • Novartis Investigative Site
    Oran, 31000, Algeria
  • Novartis Investigative Site
    Caba, Buenos Aires C1221ADC, Argentina
  • Novartis Investigative Site
    Paraná, Entre Rios E3100BBJ, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1114AAN, Argentina
  • Novartis Investigative Site
    Canberra, Australian Capital Territory 2605, Australia
  • Novartis Investigative Site
    Concord NSW, New South Wales 2139, Australia
  • Novartis Investigative Site
    Gosford, New South Wales 2250, Australia
  • Novartis Investigative Site
    Kingswood, New South Wales 2747, Australia
  • Novartis Investigative Site
    Kogarah, New South Wales 2217, Australia
  • Novartis Investigative Site
    Liverpool, New South Wales 2170, Australia
  • Novartis Investigative Site
    St. Leonards, New South Wales 2065, Australia
  • Novartis Investigative Site
    Westmead, New South Wales 2145, Australia
  • Novartis Investigative Site
    Douglas, Queensland 4810, Australia
  • Novartis Investigative Site
    Woolloongabba, Queensland 4102, Australia
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    Bedford Park, South Australia 5042, Australia
  • Novartis Investigative Site
    Hobart, Tasmania 7000, Australia
  • Novartis Investigative Site
    Box Hill, Victoria 3128, Australia
  • Novartis Investigative Site
    Clayton, Victoria 3168, Australia
  • Novartis Investigative Site
    Fitzroy, Victoria 3065, Australia
  • Novartis Investigative Site
    Heidelberg, Victoria 3084, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3050, Australia
  • Novartis Investigative Site
    Wodonga, Victoria 3690, Australia
  • Novartis Investigative Site
    Nedlands, Western Australia 6009, Australia
  • Novartis Investigative Site
    Perth, Western Australia 6000, Australia
  • Novartis Investigative Site
    Salvador, BA 41253-190, Brazil
  • Novartis Investigative Site
    Goiania, GO 74605-020, Brazil
  • Novartis Investigative Site
    Curitiba, PR 81520-060, Brazil
  • Novartis Investigative Site
    Porto Alegre, RS 90430-091, Brazil
  • Novartis Investigative Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Novartis Investigative Site
    Vancouver, British Columbia V6Z1Y6, Canada
  • Novartis Investigative Site
    Moncton, New Brunswick E1C 6Z8, Canada
  • Novartis Investigative Site
    Saint John, New Brunswick E2L 4L2, Canada
  • Novartis Investigative Site
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
  • Novartis Investigative Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Novartis Investigative Site
    Barrie, Ontario L4M 6M2, Canada
  • Novartis Investigative Site
    Brampton, Ontario L6R 3J7, Canada
  • Novartis Investigative Site
    Hamilton, Ontario L8V 5C2, Canada
  • Novartis Investigative Site
    London, Ontario N6A 4G5, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1H 8L6, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Weston, Ontario M9N 1N8, Canada
  • Novartis Investigative Site
    Windsor, Ontario N8W 2X3, Canada
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Québec, Quebec G1J 1Z4, Canada
  • Novartis Investigative Site
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Novartis Investigative Site
    Alexandria, 21131, Egypt
  • Novartis Investigative Site
    Cairo, 11566, Egypt
  • Novartis Investigative Site
    Cairo, Egypt
  • Novartis Investigative Site
    Mansoura, 35516, Egypt
  • Novartis Investigative Site
    Tamil Nadu, Chennai 600035, India
  • Novartis Investigative Site
    Pune, Maharashtra 411004, India
  • Novartis Investigative Site
    Vellore, Tamil Nadu 632004, India
  • Novartis Investigative Site
    Jerusalem, 9112001, Israel
  • Novartis Investigative Site
    Petach Tikva, 49100, Israel
  • Novartis Investigative Site
    Ramat Gan, 5266202, Israel
  • Novartis Investigative Site
    Beirut, 166830, Lebanon
  • Novartis Investigative Site
    Saida, 652, Lebanon
  • Novartis Investigative Site
    Pulau Pinang, 10990, Malaysia
  • Novartis Investigative Site
    Selangor, 68000, Malaysia
  • Novartis Investigative Site
    Hermosillo, Sonora 83000, Mexico
  • Novartis Investigative Site
    San Luis Potosi, 78416, Mexico
  • Novartis Investigative Site
    Muscat, 123, Oman
  • Novartis Investigative Site
    Arkhangelsk, Russia 163045, Russian Federation
  • Novartis Investigative Site
    Novosibirsk, Russia 630051, Russian Federation
  • Novartis Investigative Site
    Perm, Russia 614077, Russian Federation
  • Novartis Investigative Site
    Ryazan, Russia 390039, Russian Federation
  • Novartis Investigative Site
    St Petersburg, Russia 197341, Russian Federation
  • Novartis Investigative Site
    Tumen, Russia 625023, Russian Federation
  • Novartis Investigative Site
    Ekaterinburg, 620137, Russian Federation
  • Novartis Investigative Site
    Irkutsk, 664079, Russian Federation
  • Novartis Investigative Site
    Moscow, 125167, Russian Federation
  • Novartis Investigative Site
    Moscow, 125284, Russian Federation
  • Novartis Investigative Site
    Nizhnii Novgorod, 603126, Russian Federation
  • Novartis Investigative Site
    Rostov-on-Don, 344022, Russian Federation
  • Novartis Investigative Site
    Rostov-on-Don, 344090, Russian Federation
  • Novartis Investigative Site
    St Petersburg, 191024, Russian Federation
  • Novartis Investigative Site
    St-Petersburg, 197022, Russian Federation
  • Novartis Investigative Site
    Tula, 300053, Russian Federation
  • Novartis Investigative Site
    Dammam, 15215, Saudi Arabia
  • Novartis Investigative Site
    Jeddah, 21423, Saudi Arabia
  • Novartis Investigative Site
    Jeddah, 21499, Saudi Arabia
  • Novartis Investigative Site
    Riyadh, 11211, Saudi Arabia
  • Novartis Investigative Site
    Riyadh, 11426, Saudi Arabia
  • Novartis Investigative Site
    Soweto, Gauteng 2013, South Africa
  • Novartis Investigative Site
    Bloemfontein, 9301, South Africa
  • Novartis Investigative Site
    Observatory, 7925, South Africa
  • Novartis Investigative Site
    Parktown, 2193, South Africa
  • Novartis Investigative Site
    Pretoria, 0002, South Africa
  • Novartis Investigative Site
    Taipei, Taiwan, ROC 112, Taiwan
  • Novartis Investigative Site
    Lin-Kou, 33305, Taiwan
  • Novartis Investigative Site
    Niaosong Township, 83301, Taiwan
  • Novartis Investigative Site
    Taichung, 40447, Taiwan
  • Novartis Investigative Site
    Chiang Mai, 50200, Thailand
  • Novartis Investigative Site
    Muang, 40002, Thailand
  • Novartis Investigative Site
    Sousse, Tunisie 4000, Tunisia
  • Novartis Investigative Site
    Tunis, 1008, Tunisia
  • Novartis Investigative Site
    Dubai, United Arab Emirates
09

References and documents

Publications

  • Hughes TP, Munhoz E, Aurelio Salvino M, Ong TC, Elhaddad A, Shortt J, Quach H, Pavlovsky C, Louw VJ, Shih LY, Turkina AG, Meillon L, Jin Y, Acharya S, Dalal D, Lipton JH. Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. Br J Haematol. 2017 Oct;179(2):219-228. doi: 10.1111/bjh.14829. Epub 2017 Jul 12. PubMed 28699641 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2010
First posted
Dec 6, 2010
Start
Apr 2011
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results first posted
Mar 3, 2016
Last update
Mar 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01254188
Responsible party
Sponsor
First posted
Dec 6, 2010
Start date
Apr 2011
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Mar 3, 2016
Last update
Mar 3, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion